about
P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line.Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells.Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cellsOct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker.p73: a chiaroscuro gene in cancer.Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyBase excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.Across the universe of K-RAS mutations in non-small-cell-lung cancer.Genetic markers for prediction of treatment outcomes in ovarian cancer.Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo.∆Np73beta induces caveolin-1 in human non-small cell lung cancer cell line H1299.The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugsCombination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.Effects of inducible overexpression of DNp73alpha on cancer cell growth and response to treatment in vitro and in vivo.DNA repair gene polymorphisms in non-small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer.Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.ΔNp63 expression is associated with poor survival in ovarian cancerCo-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approachp73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesisRole of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patientsTherapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor modelsRELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of CarcinomaLKB1 Deficiency Renders NSCLC Cells Sensitive to ERK InhibitorsExploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME TrialMetformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLCOral prolonged-release Oxycodone-Naloxone: analgesic response, safety profile, and factors influencing the response in advanced cancer patientsAssessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
P50
Q32061496-617DAB0D-F562-4D56-8AA0-3C4B4534CC75Q34104005-10CC6F5C-B3D5-4B8B-91B3-1503F49DF036Q34202863-3754D2AD-C1E1-499E-824F-F4A0C7918BD8Q34611461-FEE510EB-3C33-4A53-A87F-FFA576524AB0Q34618259-BF21DA62-15BE-4519-BFA1-425F62B40B24Q34663620-6461B724-07FB-4D89-8E2F-8EF3A6A3FCE7Q36287562-5782CCE8-36EB-4C3A-B04C-AEB3C021EFF4Q36545375-386B9ADF-6AB5-4BA4-AA50-3E48CAB97074Q36557507-60DEDBBC-347E-4539-9579-2610736F0A86Q38153826-CFBE9153-EA56-4B67-80D6-6B1F8D44DFADQ38227080-FFB3EFCD-CC89-4433-B425-385FADE9E3E1Q38762944-3A61B63C-26A3-4BF2-9377-45DF7F351D6CQ38838216-F69297D5-CEE7-4953-8512-D0040CC2CA58Q39102558-A588AFBA-4493-481A-82F7-269F27C78A19Q40386120-81D1B9A2-3F84-452B-9FCF-77E1220C0580Q40426270-25FB5D09-1A56-4206-A562-A0EF36DC1259Q40659578-DD169CB4-EFF5-496D-84D4-1FD31A43DC27Q40810940-AF360019-8456-4DF4-9304-2273EC1C6EA7Q41548711-284F6723-DCEF-4E4A-82C0-BD752299C225Q41949668-BA017C44-C83C-4D99-AAE7-04E75CC79CE5Q42330188-3600B227-7E65-416C-8714-8C8A036D0E83Q44386340-9B5BC37C-9B1D-441B-946B-D73197A1B47EQ48223594-61D9472C-7A8A-4613-A6F8-C17606ED301EQ57819147-AFBE18DB-0162-472D-BBFE-0663E686897DQ59793918-DE482B9F-E40B-41DA-B878-E18020A063DFQ60043723-601532CA-9BF5-459F-BF97-CF928EE7D2D8Q61826799-E53D418C-58D9-4FC5-8E55-63CB19678B28Q61884094-9B0FD710-F6A2-4B6F-A94E-60C8F87B5A5AQ89478898-61091538-571E-49F3-9DC4-4416C1A62994Q90392271-9D14B6C3-50D3-485D-942F-7DCDC1742053Q90849096-7A83E193-944B-43A1-8B83-0779CD1269AFQ90928136-8ADA7A56-1B93-48A8-B289-05E62E306998Q91159351-FEC0E2D0-5ABC-4A40-BAF7-67584CDBE0A1Q92653851-25DDABF2-0139-4A0C-B440-3DCC7C7D167DQ93016783-45AC3DE2-D30E-4FBC-9D7A-91706C1672B9
P50
description
researcher ORCID ID = 0000-0001-9379-0301
@en
wetenschapper
@nl
name
M Marabese
@ast
M Marabese
@en
M Marabese
@es
M Marabese
@nl
type
label
M Marabese
@ast
M Marabese
@en
M Marabese
@es
M Marabese
@nl
prefLabel
M Marabese
@ast
M Marabese
@en
M Marabese
@es
M Marabese
@nl
P106
P1153
56244222300
P31
P496
0000-0001-9379-0301